Clinical Trials Directory

Trials / Completed

CompletedNCT00471952

Maxalt 10mg Plus Caffeine 75mg in the Acute Treatment of Migraine Headache

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
50 (actual)
Sponsor
Diamond Headache Clinic · Academic / Other
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Accepted

Summary

The purpose of this study is to evaluate the effect of rizatriptan, alone or combined with caffeine for treating acute attacks of migraine. Each subject will have 3 months to treat 3 acute migraine headache attacks. Each subject will be dispensed one box containing 3 packets of study medication labeled for Headache #1, Headache #2, or Headache #3. Each packet wil contain either Maxalt 10mg MLT or a Maxalt placebo (sugar pill), and a capsule containing either caffeine 75mg or a capsule containing placebo (sugar). One headache will be treated with a combination of Maxalt 10mg MLT and caffeine. Another headache will be treated with a combination of Maxalt 10mg MLT and a capsule containing placebo. A third headache will be treated with just placebo. Neither the subject, the study coordinator, or your study doctor will know in which order you will receive the three different treatments. This information is available in case of emergency.

Detailed description

Oral Maxalt has an extensive record of providing relief of acute migraine headache with 2 hours in the vast majority of patients, especially when undertaken as an early intervention strategy. Caffeine has been demonstrated to have analgesic effects in patients treating tension type headache and is found as part of a combination including aspirin and acetaminophen as a treatment for acute migraine headache. The mechanism by which Maxalt relieves migraine headache is believed to be through action on 5HT1B/1D receptors both on blood vessels as well as centrally. Caffeine may have effects on relief of migraine through modifying norepinephrine related mechanisms which have been suggested through clinical research. Patients commonly report that they may obtain partial or complete relief of their migraines by consuming the modest amounts of caffeine found in a cup of coffee. this is estimated to be approximately 100mg per cup. The analgesic effects of caffeine appear to be most significant in the first 3 hours after ingestion. Recent work suggests that intervention in migraine when the pain is still mild and has not persisted for a prolonged duration may increase the likelihood of complete migraine response. Therefore, the combination of the two agents with activity in migraine that work early in the migraine process, have good tolerability at the proposed doses and working via different mechanism may increase the likelihood of patients achieving better response with their migraine treatment than that which is currently available.

Conditions

Interventions

TypeNameDescription
DRUGMaxalt 10mg MLT plus Caffeine 75mgOne migraine attack will be treated
DRUGMaxalt 10mg MLT plus PlaceboOne migraine attack will be treated with Maxalt 10mg plus placebo
DRUGPlacebo + PlaceboOne migraine attack will be treated with double placebo

Timeline

Start date
2007-04-01
Primary completion
2008-02-01
Completion
2008-04-01
First posted
2007-05-10
Last updated
2012-04-25

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00471952. Inclusion in this directory is not an endorsement.